Clinical trials: Cushing's Disease
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome, Ectopic Corticotropin Syndrome
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
- Conditions
- Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma
- Trial name
- NCT02468193
- Testing
- Osilodrostat
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.
- Trial name
- NCT00422201
- Testing
- Mifepristone
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- HRA Pharma
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome, Cushing Disease
Open-label Treatment in Cushing's Syndrome
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
- Trial name
- OPTICS (NCT03621280)
- Testing
- Levoketoconazole
- Where
- 30 sites in United States, Bulgaria and 9 more
- Volunteers
- 51 people
- Sponsor
- Cortendo AB
Cushing's Disease
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
- Trial name
- LINC-4 (NCT02697734)
- Testing
- osilodrostat
- Where
- 36 sites in United States, Belgium and 12 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Cushing's Disease
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
- Trial name
- NCT00434148
- Testing
- Pasireotide
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals